Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Behavioural Neurology
|
February 4, 2014
Clock-drawing in neurological disorders
G Dal Pan, Y Stern, M Sano, et al.
Clinical Pharmacology and Therapeutics
|
December 16, 2015
The FDA's sentinel initiative--A comprehensive approach to medical product surveillance
R Ball, M Robb, S A Anderson, et al.
International Journal of Peptide and Protein Research
|
November 1, 1983
Role of the carboxamide groups of the asparagine and glycinamide residues of oxytocin. Syntheses and biological properties of [5-beta-cyanoalanine] oxytocin and [9-alpha-aminoacetonitrile] oxytocin
U Roy, D Gazis, G Dal Pan, et al.
Clinical Pharmacology and Therapeutics
|
February 12, 2015
Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs
J Bohn, C Kortepeter, M Muñoz, et al.
Clinical Pharmacology and Therapeutics
|
June 7, 2013
The future of population-based postmarket drug risk assessment: a regulator's perspective
T A Hammad, G A Neyarapally, S Iyasu, et al.
Clinical Pharmacology and Therapeutics
|
March 2, 2012
Drug-induced PML: a global agenda for a global challenge
M Vinhas de Souza, B Keller-Stanislawski, K Blake, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Behavioural Neurology
|
February 4, 2014
Clock-drawing in neurological disorders
G Dal Pan, Y Stern, M Sano, et al.
Clinical Pharmacology and Therapeutics
|
December 16, 2015
The FDA's sentinel initiative--A comprehensive approach to medical product surveillance
R Ball, M Robb, S A Anderson, et al.
International Journal of Peptide and Protein Research
|
November 1, 1983
Role of the carboxamide groups of the asparagine and glycinamide residues of oxytocin. Syntheses and biological properties of [5-beta-cyanoalanine] oxytocin and [9-alpha-aminoacetonitrile] oxytocin
U Roy, D Gazis, G Dal Pan, et al.
Clinical Pharmacology and Therapeutics
|
February 12, 2015
Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs
J Bohn, C Kortepeter, M Muñoz, et al.
Clinical Pharmacology and Therapeutics
|
June 7, 2013
The future of population-based postmarket drug risk assessment: a regulator's perspective
T A Hammad, G A Neyarapally, S Iyasu, et al.
Clinical Pharmacology and Therapeutics
|
March 2, 2012
Drug-induced PML: a global agenda for a global challenge
M Vinhas de Souza, B Keller-Stanislawski, K Blake, et al.
Page
of 1